NASDAQ · DCOY
Decoy Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DCOY: Nov 13, 2026
Decoy Therapeutics Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-21.73.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Quiver Quantitative- RTTNews · Sep 29, 8:15 AM EDTDecoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoV(RTTNews) – Tuesday, Decoy Therapeutics (DCOY) said preclinical pharmacokinetic data support once-weekly intranasal dosing of its lead program DCOY-CoV, designed to protect against endemic human coronaviruses.
- RTTNews · Sep 22, 9:01 AM EDTDecoy Expands Pan-Filovirus Efforts Through FDA Pathway; Stock Up(RTTNews) – Decoy Therapeutics, Inc. (DCOY) is expanding the potential reach of its antiviral platform by exploring a pan-filovirus program aimed at combating deadly viruses such as Ebola and Marburg, while pursuing non-dilutive funding and public health partnership to support de
- RTTNews · Sep 9, 2:36 PM EDTClinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More(RTTNews) – Biotech and medical device stocks saw notable moves Wednesday, led by Opus Genetics, which surged more than 27% following positive clinical data. Quantum BioPharma gained after receiving FDA clearance for a Phase 2 MS trial, while Pulse Biosciences rallied more than 1
- RTTNews · Jun 29, 10:58 PM EDTTop Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?(RTTNews) – Today's top gainers include Universe Pharma, which expanded its pharmaceutical patent portfolio; Decoy Therapeutics, following the announcement of a PIPE financing; QuidelOrtho, on reports that it is exploring the sale of one of its business units; and SELLAS, which i
- RTTNews · Jun 29, 6:10 AM EDTDecoy Therapeutics Enters Up To $21 Mln PIPE Financing; Stock Surges In Pre-Market(RTTNews) – Decoy Therapeutics, Inc. (DCOY), a clinical-stage biotech company, announced it entered into a securities purchase agreement with a single healthcare-focused institutional investor for a private investment in public equity (PIPE). The financing consists of $3.5 millio
- RTTNews · Jun 5, 10:26 AM EDTWeekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN(RTTNews) – This week, the biotech sector saw a wave of regulatory approvals in the U.S., alongside study halts, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical study data readouts spanned multiple therapeutic areas, inclu
- RTTNews · Jun 1, 10:45 AM EDTDecoy Therapeutics Partners With HVIVO To Advance D-MAV Into Clinical Study; Stock Up(RTTNews) – Decoy Therapeutics Inc. (DCOY), a pre-clinical stage biotechnology company, announced that it has entered into a strategic development agreement with a European based pharmaceutical service partner, hVIVO plc (HVO.L) to advance its lead Designable Multi-Antiviral or D
- RTTNews · May 26, 3:50 AM EDTTop Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch(RTTNews) – Biotech stocks witnessed strong momentum on Friday, with Akari Therapeutics leading the pack, driven by encouraging preclinical pancreatic cancer data for AKTX-101. MetaVia, GeoVax, Polyrizon, and Sol-Gel were also some of the companies that captured Wall Street's at
- Fintel · Mar 27, 10:04 AM EDTDecoy Therapeutics (DCOY) Price Target Increased by 1,100.00% to 30.60The average one-year price target for Decoy Therapeutics (NasdaqCM:DCOY) has been revised to $30.60 / share. This is an increase of 1,100.00% from the prior estimate of $2.55 dated February 21, 2026. The price target is an average of many targets provided by a
- RTTNews · Jan 13, 10:32 AM ESTDecoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up(RTTNews) – Decoy Therapeutics, Inc. (DCOY), a preclinical biopharmaceutical company, announced on Tuesday that the development of its peptide-conjugate antiviral platform has reached a Global Access Commitment Agreement (GACA) with the Gates Foundation to support making counterm
- RTTNews · Aug 14, 10:23 AM EDTSalarius Pharmaceuticals To Implement 1-for-15 Reverse Stock Split(RTTNews) – Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company, Thursday announced that it will implement a 1-for-15 reverse stock split effective August 15.
- Quiver Quantitative · Jul 14, 8:42 AM EDTSalarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy TherapeuticsSalarius Pharmaceuticals receives Nasdaq extension to regain compliance as it prepares for merger with Decoy Therapeutics.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Decoy Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.